BR0316123A - Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico - Google Patents

Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico

Info

Publication number
BR0316123A
BR0316123A BR0316123-4A BR0316123A BR0316123A BR 0316123 A BR0316123 A BR 0316123A BR 0316123 A BR0316123 A BR 0316123A BR 0316123 A BR0316123 A BR 0316123A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
aqueous pharmaceutical
patient
treatment
treating
Prior art date
Application number
BR0316123-4A
Other languages
English (en)
Inventor
Peter Edman
Karin Wingstrand
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0316123A publication Critical patent/BR0316123A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA AQUOSA, USO DE UMA FORMULAçãO FARMACêUTICA AQUOSA, E, MéTODO DE TRATAMENTO DE UM PACIENTE COM NECESSIDADE DE TRATAMENTO ANTITROMBóTICO". Uma formulação farmacêutica aquosa compreendendo o inibidor de trombina HOOC-CH~ 2~-(R)-Cgl-Aze-Pab (melagatran), ou um derivado farmaceuticamente aceitável deste, um processo para a preparação de uma tal formulação farmacêutica, o uso de uma tal formulação no tratamento de tromboembolismo assim como um método de tratamento de um paciente com necessidade de tratamento antitrombótico e tromboembolismo pelo uso de dita formulação através da administração nasal.
BR0316123-4A 2002-11-12 2003-11-11 Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico BR0316123A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0203349A SE0203349D0 (sv) 2002-11-12 2002-11-12 New use
PCT/SE2003/001738 WO2004043486A1 (en) 2002-11-12 2003-11-11 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism

Publications (1)

Publication Number Publication Date
BR0316123A true BR0316123A (pt) 2005-09-27

Family

ID=20289548

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316123-4A BR0316123A (pt) 2002-11-12 2003-11-11 Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico

Country Status (13)

Country Link
US (1) US20060014699A1 (pt)
EP (1) EP1581255A1 (pt)
JP (1) JP2006507323A (pt)
KR (1) KR20050074598A (pt)
CN (1) CN1711104A (pt)
AU (1) AU2003276801A1 (pt)
BR (1) BR0316123A (pt)
CA (1) CA2504480A1 (pt)
MX (1) MXPA05005118A (pt)
NO (1) NO20052313L (pt)
SE (1) SE0203349D0 (pt)
WO (1) WO2004043486A1 (pt)
ZA (1) ZA200503711B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
WO2011038068A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy

Also Published As

Publication number Publication date
KR20050074598A (ko) 2005-07-18
CN1711104A (zh) 2005-12-21
WO2004043486A1 (en) 2004-05-27
CA2504480A1 (en) 2004-05-27
SE0203349D0 (sv) 2002-11-12
NO20052313L (no) 2005-06-06
US20060014699A1 (en) 2006-01-19
EP1581255A1 (en) 2005-10-05
WO2004043486A8 (en) 2005-03-17
JP2006507323A (ja) 2006-03-02
MXPA05005118A (es) 2005-07-01
ZA200503711B (en) 2006-11-29
AU2003276801A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
NO20065904L (no) Terapeutiske forbindelser
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
EA200601418A1 (ru) ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
HRP20090022T3 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
NO20052313L (no) Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av
SE0102057D0 (sv) New Salts I
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.